Abstract Body

Despite the great success of antiviral therapy (ART), treatment is life long for the majority of people living with HIV (PLWH). Antiviral treatment is simple and relatively cheap and close to 60% of PLWH have access to treatment. However, ART is still not available or secure for many, drug resistance is common globally and there are emerging toxicities from some of the most potent antivirals. Modelling studies of the cost and impact of a cure have identified that the need for frequent follow up and viral load testing after cessation of ART, unpredictable viral rebound and lack of protection from re-infection will all reduce the impact of a cure at a population level. Therefore there is now an increasing focus in the field to achieve a true cure and not HIV remission. Understanding where and how virus persists is key to the development of novel interventions to achieve a cure. Recent work has identified the significant contribution of proliferation of infected cells to HIV persistence on ART. Understanding the drivers of proliferation and clonal expansion remains a key unanswered question. In addition, multiple factors including the site of integration can influence the transcriptional activity of a virus and a deeper state of latency may reduce the chance of viral rebound off ART. Finally, the majority of viruses that persist on ART are defective and unable to replicate. A cure may therefore occur with loss of intact virus but persistence of only defective forms. New high throughput assays can now quantify intact and defective viruses more accurately and positive emission tomography and imaging can potentially identify tissue reservoirs of virus persistence. Multiple strategies to achieve a cure are being evaluated in both animal models and human clinical trials including combination immunotherapy to reduce the viral burden and enhance immune clearance. Results from recent clinical trials of newer latency reversing agents, immune checkpoint blockade and other immune adjuvants, broadly neutralising antibodies and gene therapy will be discussed. It is likely that in the next few years long acting and implantable antiretrovirals will be available and these newer modalities may address many of the current challenges of ART. Therefore, ongoing consultation is needed with PLWH and all other stakeholders to develop an acceptable target product profile for a cure that will have the greatest personal and population impact and can be implemented at scale.